相关实验视频

Updated: May 5, 2026

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Automated Radiochemical Synthesis of [18F]3F4AP: A Novel PET Tracer for Imaging Demyelinating Diseases

Published on: May 29, 2017

合成和临床前评估F标记的1,5-二甲衍生物用于COX-2表达的成像

Wenjun Miao¹, Meixian Yang¹, Zhiping Peng¹

¹Department of Radiological Medicine and Oncology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, 400016, People's Republic of China.

Molecular diversity

|August 21, 2025

概括

这项研究开发了[¹⁸F]6,一种用于循环氧化酶-2 (COX-2) 成像的新型放射标志物. 虽然在体外稳定,但体内没有瘤积累,因此需要进一步优化临床使用.

科学领域:

放射化学
分子成像
癌症学

背景情况:

循环氧化酶-2 (COX-2) 是一个关键的癌症生物标志物,参与血管生成和瘤进展.
现有的COX-2放射标志物缺乏临床应用,突出显示需要新的成像剂.

研究的目的:

合成和评估一种新型的1,5-diarylpyrrole衍生物[¹⁸F]6,作为用于COX-2成像的潜在PET放射标志物.
在体外和体内评估[¹⁸F]6的放射合成,稳定性和结合特性.

主要方法:

通过一阶段的F-三甲基化进行[F]6的放射合成.
使用HPLC评估放射性化学产量,纯度和分子活性.
在盐水和FBS中进行实验室稳定性研究,以及使用MCF-7细胞的特定结合试验.
在患有MCF-7瘤的小鼠中进行微PET/CT成像.

主要成果:

[¹⁸F]6在90分钟内合成,RCY为2-6%,RCP>98%和足够的活动.
在Celecoxib阻断的MCF-7细胞中,放射性标记物表现出良好的体外稳定性和特异性结合.
在携带瘤的小鼠体内没有观察到[¹⁸F]6的显著瘤积累.

结论:

[¹⁸F]6在COX-2成像中表现出有希望的体外特征.
在体内瘤向不充分可能与模型中 activity低或COX-2表达不充分有关.
进一步优化放射合成和评估更合适的模型是必要的,以验证[¹⁸F]6作为COX-2成像剂的潜力.

关键词:

标有18F的1,5-二甲衍生物 COX-2成像剂癌症无线电追踪器

更多相关视频

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production

Published on: October 26, 2018

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Technical Aspect of the Automated Synthesis and Real-Time Kinetic Evaluation of [11C]SNAP-7941

Published on: April 28, 2019

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...